

Supplementary Table S2. Demographic, clinical and molecular characteristics of b/tsDMARD-naïve RA patients recruited for *ex-vivo* studies (Cohort 1).

Clinical parameters	RA naïve patients (n=48)
Male/Female (n/n)	16/32
Age, years (mean $\pm$ SD)	58.63 $\pm$ 11.86
Disease evolution, years (mean $\pm$ SD)	7.32 $\pm$ 7.68
TJC (mean $\pm$ SD)	6.81 $\pm$ 5.80
SJC (mean $\pm$ SD)	3.65 $\pm$ 3.89
DAS28-CRP (mean $\pm$ SD)	4.48 $\pm$ 1.18
SDAI (mean $\pm$ SD)	25.69 $\pm$ 11.98
CDAI (mean $\pm$ SD)	24.29 $\pm$ 11.49
HAQ (mean $\pm$ SD)	1.35 $\pm$ 0.67
Smoking (n, %)	13, 27.08%
Hypertension (n, %)	19, 39.58%
Laboratory parameters	

CRP, mg/mL (mean $\pm$ SD)	14.02 $\pm$ 23.97
ESR, mm/h (mean $\pm$ SD)	16.49 $\pm$ 15.63
ACPAs positivity (n, %)	34, 70.83%
RF positivity (n, %)	40, 83.33%
Treatments	
Corticosteroids (n, %)	35, 72.92%
NSAIDs (n, %)	25, 52.08%
cDMARDs (n, %)	43, 89.58%

TJC (Tender Joint Count); SJC (Swollen Joint Count); DAS28-CRP (Disease Activity Score); SDAI (Simplified Disease Activity Index); CDAI (Clinical Disease Activity Index); HAQ (Health Assessment Questionnaire); CRP (C-reactive protein); ESR (Erythrocyte sedimentation rate); ACPA (Anti-citrullinated protein antibodies); RF (Rheumatoid Factor); NSAID (Non-steroidal anti-inflammatory drug); cDMARD (Conventional DMARDs).